MWNA
BCRX icon

Marshall Wace North America’s BioCryst Pharmaceuticals BCRX Stock Holding History

Marshall Wace North America’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-865,538
Closed -$8.8M – 1458
2021
Q1 		$8.8M Sell
865,538
-1,932,985
-69% -$19.9M 0.04% 421
2020
Q4 		$20.8M Buy
2,798,523
+1,317,865
+89% +$6.79M 0.09% 246
2020
Q3 		$5.09M Hold
1,480,658
– – 0.03% 385
2020
Q2 		$7.05M Buy
+1,480,658
New +$5.91M 0.05% 319
2017
Q4 		– Sell
-84,895
Closed -$424K – 1372
2017
Q3 		$424K Buy
+84,895
New +$435K ﹤0.01% 1101

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Marshall Wace North America's BCRX Position: Q2 2021 in Review

Marshall Wace North America sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2021, closing a stake of 865,538 shares — an estimated $8.8M sold.

Marshall Wace North America first reported a position in BCRX in Q3 2017 and held it in 5 quarters. The position peaked at $20.8M in Q4 2020. 195 funds tracked by Wall St. Rank hold BCRX as of Q2 2021.

  • Marshall Wace North America reported no remaining BioCryst Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 865,538 BioCryst Pharmaceuticals shares in Q2 2021, an estimated $8.8M.
  • Marshall Wace North America first reported a position in BioCryst Pharmaceuticals in Q3 2017 and held it in 5 quarters.
  • Marshall Wace North America's BioCryst Pharmaceuticals position peaked at $20.8M in Q4 2020.
  • 195 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.